[(S)-1-((S)-2-{5-[4-(6-{(S)-2-[1-((R)-2-methoxycarbonylamino-2-phenylacetyl)-pyrrolidin-2-yl]-3H-benzoimidazol-5-yl}-thieno[3,2-b]-thiophen-3-yl)-phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carbonyl)-2-methylpropyl]-carbamic acid methyl ester | 1312547-21-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(S)-1-((S)-2-{5-[4-(6-{(S)-2-[1-((R)-2-methoxycarbonylamino-2-phenylacetyl)-pyrrolidin-2-yl]-3H-benzoimidazol-5-yl}-thieno[3,2-b]-thiophen-3-yl)-phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carbonyl)-2-methylpropyl]-carbamic acid methyl ester
• 英文别名: methyl N-[(1R)-2-[(2S)-2-[6-[3-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]thieno[3,2-b]thiophen-6-yl]-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
• CAS: 1312547-21-9
• 化学式: C₄₇H₄₈N₈O₆S₂
• 分子量: 885.08
• InChiKey: AWPQGPJNSHZCOL-BTSKBWHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  63
• 可旋转键数：
  13
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  231
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (S)-2-{6-[6-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)thieno[3,2-b]thiophen-3-yl]-1H-benzoimidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester 在 盐酸 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 [(S)-1-((S)-2-{5-[4-(6-{(S)-2-[1-((R)-2-methoxycarbonylamino-2-phenylacetyl)-pyrrolidin-2-yl]-3H-benzoimidazol-5-yl}-thieno[3,2-b]-thiophen-3-yl)-phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carbonyl)-2-methylpropyl]-carbamic acid methyl ester
  参考文献：
  名称：

  5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS

  摘要：

  公开号：

  EP2513113B1

文献信息

• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20150023913A1

  公开（公告）日：2015-01-22

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR
  申请人：Dousson Cyril B.

  公开号：US20120252721A1

  公开（公告）日：2012-10-04

  Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.

  本文提供了一种治疗或预防受体内药物耐药性丙型肝炎病毒感染的方法，包括向受体内注射一种5,5-融合杂芳烃丙型肝炎病毒抑制剂化合物，例如，公式I、IA或IB中的化合物。
• Combinations of Hepatitis C Virus Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160158200A1

  公开（公告）日：2016-06-09

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• PHARMACEUTICAL COMPOSITIONS COMPRISING A 5,5-FUSED HETEROARYLENE FLAVIVIRIDAE INHIBITOR AND THEIR USE FOR TREATING OR PREVENTING FLAVIVIRIDAE INFECTION
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US20170135990A1

  公开（公告）日：2017-05-18

  Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection.